Abstract
The interaction between intracellular signalling pathways mediated by Ca 2+ and cAMP (Ca 2+ /cAMP signalling interaction) is now well-accepted as a vital cellular process for mammalians. In the neuroscience field, it has opened a new avenue for the drug development more effective, and safer, for the treatment of Alzheimer´s and neurodegenerative diseases. It has been almost 4 years since we revealed the involvement of the Ca 2+ /cAMP signalling interaction in the enigma of the so-called "calcium paradox". Interestingly, the "calcium paradox" initiated decades ago, when numerous clinical studies have reported that prescription of L-type Ca 2+ channel blockers (CCBs) for hypertensive patients decreased arterial pressure, but produced typical symptoms of sympathetic hyperactivity. Despite these adverse effects of CCBs have been initially attributed to adjust reflex of arterial pressure, during almost four decades this enigmatic phenomenon (the socalled "calcium paradox") remained unclear. In 2013, through creative experiments, we discovered that this phenomenon was resulting of increment of transmitter release from sympathetic neurons, and adrenal chromaffin cells, stimulated by CCBs due to its interference on the Ca 2+ /cAMP signalling interaction. Thus, pharmacological handling of the Ca
Introduction
Nowadays, the interaction between intracellular signalling pathways mediated by Ca 2+ and cAMP (Ca 2+ /cAMP signalling interaction) is well-recognized as a vital cellular process for mammalians. This interaction has opened a novel pathway for the drug development more effective, and safer, to treating diseases related to the neuroscience field, such as Alzheimer´s and other neurodegenerative diseases. The results which demonstrated the involvement of the Ca 2+ /cAMP signalling interaction in the enigma of the so-called "calcium paradox" have completed a 4-years anniversary. For understanding the "calcium paradox", we should return to the past. Indeed, the stimulus-secretion concept to describe neurotransmitters, and hormones, release has been resulted from ingenious experiments performed by Douglas and Rubin in the 1960s [1] . content of transmitter in the secretory vesicles (please see figure 1 ) and enhancing of rate of transmitter release. Thus, by elevating cAMP levels, this second messenger may enhance the release of Ca 2+ from ER. Indeed, Ca 2+ is crucial for the transmitter release, participating in virtually all the previous mentioned processes: content of transmitter in the secretory vesicles and rate of transmitter release. Figure 1 shows how the pharmacological modulation of the Ca 2+ /cAMP signalling interaction could produce increase of neurotransmitter release.
Indeed, many reports have shown that increase of cytosolic cAMP concentration ([cAMP]c) stimulates neuroprotective effects [13, 14] . Thus, elevating [cAMP]c by handling Ca 2+ /cAMP signalling interaction could reduce neuronal death triggered by cytosolic Ca 2+ overload [8] [9] [10] [11] . Then, the pharmacological handling of the Ca 2+ /cAMP signalling interaction produced by combination of the L-type CCBs prescribed in the antihypertensive therapy, and [cAMP] c-enhancer compounds prescribed in the anti-depressive therapy such as rolipram, could be a novel pharmacological strategy for enhancing neurotransmission in neurological, and psychiatric disorders, resulting of neurotransmitter release deficit, and neuronal death [8] [9] [10] [11] . Figure 1 shows how the pharmacological modulation of the Ca 2+ /cAMP signalling by the Nobel laureate Erwin Neher [3] . Thus, by reducing extracellular Ca 2+ through blocking Ca 2+ channels, we should have a reducing in the neurotransmitter release. However, many studies have showed that L-type Ca 2+ channel blockers (CCBs), in concentrations below 1 μmol/L, could induce neurotransmitter release, a "paradox" [4] [5] [6] . In addition, many results have shown that cAMP increases neurotransmitter release at many synapses in autonomic nervous system of vertebrate, including sympathetic neurons [7] . We recently showed that Ca 2+ /cAMP signalling interaction participates in the regulation of transmitters release from sympathetic neurons, and adrenal chromaffin cells [8] [9] [10] [11] .
The Ca 2+ /cAMP signalling interaction as a universal concept The Ca 2+ /cAMP signalling interaction is well-recognized as a vital cellular process for mammalians. This nowadays accepted concept assumes that these signalling pathways virtually exist in all mammalian cells, regulated by adenylyl cyclases (ACs) and phosphodiesterases (PDEs) [8] [9] [10] [11] . Indeed, endoplasmic reticulum (ER) Ca 2+ channels have particularly been a forefront for the Ca 2+ /cAMP signalling interaction field, such as ryanodine receptors (RyR) [8] [9] [10] [11] . We established that Ca 2+ /cAMP signalling interaction plays a fundamental participation in the regulation of neurotransmitter release from neurons and neuroendocrine cells [8] [9] [10] [11] . Then, Ca 2+ / cAMP signalling interaction could be a novel therapeutic target for medicines.
The Ca

2+ /cAMP signalling interaction and the neuroscience field
Several medical studies have been evidencing that prescription of L-type CCBs in the antihypertensive pharmacotherapy decreased arterial pressure arterial, but produced typical clinical symptoms of sympathetic hyperactivity [12] . Despite these adverse effects of CCBs have been initially attributed to adjust reflex of arterial pressure, during almost four decades this enigmatic phenomenon named "calcium paradox" remained without additional explanation. In 2013, through creative experiments, we discovered that the "calcium paradox" phenomenon was resulting of increment of transmitter release from sympathetic neurons, and adrenal chromaffin cells, stimulated by CCBs due to its interference on the Ca 2+ /cAMP signalling interaction [9] . We showed that sympathetic-mediated contractions of the vas deferens were completely inhibited by L-type CCBs in high concentrations (>1 μmol/L), but unpredictably, and paradoxically, potentiated in concentrations below 1 μmol/L, characterized by CCBsinduced sympathetic hyperactivity [4] [5] [6] 9] . Our studies showed that this hyperactivity is caused by increment of neurotransmitter release from sympathetic neurons produced by L-type CCBs due to its interference on the Ca 2+ /cAMP signalling interaction [8] [9] [10] [11] . Briefly, the reduction of Ca 2+ influx through L-type voltage-activated Ca 2+ channels produced by CCBs enhances the adenylyl cyclase activity (and consequently elevating cAMP levels, please see figure 1 ). These CCBs-effects can be potentiated by cAMP-enhancer compounds (like PDEs inhibitors). In fact, the fundamental mechanisms by which Ca 2+ /cAMP signalling interaction may increase the transmitter release are due: increasing of interaction could produce attenuation of neuronal death.
In fact, it was showed that the prescription of L-type CCBs reduces motor symptoms, and reduces progressive neuronal death in animal model of Parkinson´s disease, suggesting that L-type CCBs are potentially viable neuroprotective pharmaceuticals [15] . Additionally, a 1-decade follow-up study (2000 to 2010), involving 82,107 hypertensive patients of more than 60 years of age, demonstrated that prescription of L-type CCBs during antihypertensive therapy reduces risk of dementia in these patients, indicating that these pharmaceuticals could be clinically used to treat Alzheimer´s disease [16] . These findings for the neuroprotective CCBseffects have been demonstrated in 1,241 elderly hypertensive patients with memory impairment [17] . The prescription of CCBs decreased the risk of cognitive impairment, and Alzheimer´s disease, independently of blood pressure levels when compared to patients not receiving CCBs [17] . These findings highlight the concept that attenuation of cytosolic Ca 2+ overload produced by L-type CCBs due to blockade of Ca 2+ influx could be a successful pharmacological strategy to reduce, or prevent, neuronal death in neurodegenerative diseases. Finally, these findings could open a new way for the drug development more effective, and safer, for the pharmacotherapy of Alzheimer´s and other neurodegenerative diseases [18] [19] [20] [21] [22] [23] [24] .
Conclusion
This work proposes that pharmacological interference on the Ca 2+ /cAMP signalling interaction could be a more efficient, and safer, therapeutic strategy for stimulating neurotransmission compromised by neurotransmitter release deficit, and reducing neuronal death.
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